567 related articles for article (PubMed ID: 22527106)
61. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Sedjo RL; Devine S
Breast Cancer Res Treat; 2011 Jan; 125(1):191-200. PubMed ID: 20495864
[TBL] [Abstract][Full Text] [Related]
62. Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Markopoulos C; Neven P; Tanner M; Marty M; Kreienberg R; Atkins L; Franquet A; Gnant M; Neciosup S; Tesarova P; Barni S; Deschamp V
Future Oncol; 2015; 11(2):205-17. PubMed ID: 25591836
[TBL] [Abstract][Full Text] [Related]
63. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Krekow LK; Hellerstedt BA; Collea RP; Papish S; Diggikar SM; Resta R; Vukelja SJ; Holmes FA; Reddy PK; Asmar L; Wang Y; Fox PS; Peck SR; O'Shaughnessy J
J Clin Oncol; 2016 May; 34(14):1594-600. PubMed ID: 26884554
[TBL] [Abstract][Full Text] [Related]
64. Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy.
Schmid SM; Eichholzer M; Bovey F; Myrick ME; Schötzau A; Güth U
Breast; 2012 Aug; 21(4):487-92. PubMed ID: 22153572
[TBL] [Abstract][Full Text] [Related]
65. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
66. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
67. Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Thivat E; Van Praagh I; Belliere A; Mouret-Reynier MA; Kwiatkowski F; Durando X; Mahammedi H; Dillies AF; Chollet P; Chevrier R
Oncology; 2013; 84(2):67-74. PubMed ID: 23128040
[TBL] [Abstract][Full Text] [Related]
68. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Nabieva N; Fehm T; Häberle L; de Waal J; Rezai M; Baier B; Baake G; Kolberg HC; Guggenberger M; Warm M; Harbeck N; Wuerstlein R; Deuker JU; Dall P; Richter B; Wachsmann G; Brucker C; Siebers JW; Popovic M; Kuhn T; Wolf C; Vollert HW; Breitbach GP; Janni W; Landthaler R; Kohls A; Rezek D; Noesselt T; Fischer G; Henschen S; Praetz T; Heyl V; Kühn T; Krauss T; Thomssen C; Hohn A; Tesch H; Mundhenke C; Hein A; Hack CC; Schmidt K; Belleville E; Brucker SY; Kümmel S; Beckmann MW; Wallwiener D; Hadji P; Fasching PA
Eur J Cancer; 2018 Jun; 96():82-90. PubMed ID: 29679775
[TBL] [Abstract][Full Text] [Related]
69. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
[TBL] [Abstract][Full Text] [Related]
70. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
71. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
72. Optimisation of breast cancer patients' follow-up - potential way to improve cancer care in transitional countries.
Bošković L; Gašparić M; Petrić Miše B; Petković M; Gugić D; Ban M; Jazvić M; Dabelić N; Belac Lovasić I; Vrdoljak E
Eur J Cancer Care (Engl); 2017 Jul; 26(4):. PubMed ID: 27145728
[TBL] [Abstract][Full Text] [Related]
73. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
[TBL] [Abstract][Full Text] [Related]
74. Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.
Brier MJ; Chambless D; Gross R; Su HI; DeMichele A; Mao JJ
Eur J Cancer; 2015 Sep; 51(14):1890-6. PubMed ID: 26169018
[TBL] [Abstract][Full Text] [Related]
75. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
[TBL] [Abstract][Full Text] [Related]
76. Acupuncture for joint symptoms related to aromatase inhibitor therapy in postmenopausal women with early-stage breast cancer: a narrative review.
Halsey EJ; Xing M; Stockley RC
Acupunct Med; 2015 Jun; 33(3):188-95. PubMed ID: 25733539
[TBL] [Abstract][Full Text] [Related]
77. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.
Chlebowski RT; Kim J; Haque R
Cancer Prev Res (Phila); 2014 Apr; 7(4):378-87. PubMed ID: 24441675
[TBL] [Abstract][Full Text] [Related]
78. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers.
Boonstra A; van Zadelhoff J; Timmer-Bonte A; Ottevanger PB; Beurskens CH; van Laarhoven HW
Cancer Nurs; 2013; 36(1):52-9. PubMed ID: 22495502
[TBL] [Abstract][Full Text] [Related]
79. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
80. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
